Orchard Therapeutics PLC
Jason Bablak has extensive experience in regulatory affairs and executive roles within the biotechnology and pharmaceutical industries. Jason has held positions such as Vice President of Regulatory Affairs, COO, and Vice President of Regulatory Science, overseeing regulatory strategy and activities in various companies. Their expertise includes managing day-to-day regulatory affairs, interacting with regulatory agencies, and preparing regulatory submissions.
Jason Bablak graduated from Allegheny College in 1989 with a Bachelor of Science degree in Biology and Environmental Science. Jason then attended the University of Pittsburgh School of Law from 1989 to 1992, where they obtained their Doctor of Law (J.D.) degree.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.